On Wednesday, Novo Nordisk A/S (NYSE:NVO) and Valo Health, Inc. entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease.
The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programs, primarily focused on cardiovascular disease.
Valo was eligible to receive up to $2.7 billion in milestone payments, plus R&D funding and potential royalty payments.
Also Read: Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Under the terms of the expanded agreement, Valo is entitled to receive an upfront payment, equity investment, and a potential near-term milestone payment totaling $190 million and is now eligible to receive milestone payments for up to 20 drug programs, an addition of 9 new drug programs, totaling approximately $4.6 billion, plus R&D funding and potential royalty payments.
The expanded collaboration will continue to leverage Valo's Opal Computational Platform's capabilities, key joint capabilities in human data and genetics, and Novo Nordisk's expertise in cardiometabolic diseases.
The collaboration has already identified several novel targets that may form the basis of differentiated cardiometabolic drug programs, and the companies are actively working on multiple small-molecule preclinical drug discovery programs.
On Tuesday, Variant Bio, a genomics-driven drug discovery company, announced a multi-year research collaboration with Novo Nordisk to discover novel targets for metabolic disease.
The partnership between Novo Nordisk and Variant Bio aims to identify and validate multiple novel targets with sufficient human genetic evidence to initiate human-centric drug discovery programs.
Under the terms of the agreement, Novo Nordisk said it would pay Variant Bio an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments on targets that arise from the collaboration.
Price Action: NVO stock is up 2.95% at $85.80 at the last check on Wednesday.
- Helen Of Troy Sales Decline As Beauty Products Demand Softens; Shares Plunge
Photo via Shutterstock
週三，諾和諾德A/S（紐約證券交易所代碼：NVO）和Valo Health, Inc.簽訂了擴大協議，以發現和開發肥胖、2型糖尿病和心血管疾病的新療法。
兩家公司最初於2023年9月合作達成了一項協議，該協議允許開發多達11個藥物項目，主要針對心血管疾病。
Valo有資格獲得高達27億美元的里程碑付款，外加研發資金和潛在的特許權使用費。
另請閱讀：Viking Therapeutics、Structure Therapeutics被定位爲減肥產品的主要製藥合作伙伴：分析師
根據擴大協議的條款，Valo有權獲得總額爲1.9億美元的預付款、股權投資和潛在的近期里程碑付款，現在有資格獲得多達20個藥物項目、另外9個總額約爲46億美元的新藥項目的里程碑式付款，外加研發資金和潛在的特許權使用費。
擴大合作將繼續利用Valo的Opal計算平台的能力、人類數據和遺傳學方面的關鍵聯合能力以及Novo Nordisk在心臟代謝疾病方面的專業知識。
該合作已經確定了幾種可能構成差異化心臟代謝藥物計劃基礎的新靶標，兩家公司正在積極開展多個小分子臨牀前藥物發現計劃。
週二，由基因組學驅動的藥物發現公司Variant Bio宣佈與諾和諾德進行爲期多年的研究合作，以發現代謝性疾病的新靶標。
Novo Nordisk和Variant Bio之間的合作旨在識別和驗證具有足夠人類遺傳證據的多個新靶標，以啓動以人爲本的藥物發現計劃。
根據協議條款，諾和諾德表示將向Variant Bio支付預付款和總額高達5000萬美元的額外短期研發資金，外加潛在的期權和里程碑付款，以實現合作產生的目標。
價格走勢：在週三的最後一次支票中，NVO股價上漲2.95％，至85.80美元。
- 隨着美容產品需求的疲軟，特洛伊海倫的銷售額下降；股價暴跌
照片來自 Shutterstock
